<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03894189</url>
  </required_header>
  <id_info>
    <org_study_id>Faculty Of Medicine,Beni -Suef</org_study_id>
    <nct_id>NCT03894189</nct_id>
  </id_info>
  <brief_title>The Effect of Doxapram Versus Theophylline on Diaphragmatic Function</brief_title>
  <official_title>The Effect of Doxapram Versus Theophylline on Diaphragmatic Function and Weaning From Mechanical Ventilation After Open Heart Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Doxapram is licensed for drug-induced post-anesthesia respiratory depression , arousal effect&#xD;
      and return airway protective reflexes caused by barbiturates, volatile anesthetics, nitrous&#xD;
      oxide or benzodiazepines over dosage.&#xD;
&#xD;
      Value of theophylline to stimulate the respiratory neuronal network has been examined by&#xD;
      previous studies and increases the activity of respiratory muscles, including the intercostal&#xD;
      , transversus abdominis muscles and the diaphragm, it also has bronchodilator and&#xD;
      anti-inflammatory effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized comparative study will be conducted in the post-surgical cardio-thoracic&#xD;
      intensive care unit in Beni -Suef University Hospital after approval of the department of&#xD;
      anesthesiology, surgical ICU and pain management , and cardio thoracic department and the&#xD;
      local ethics and research committee, and obtaining written informed consents from the&#xD;
      patients to compare the effect of doxapram versus theophylline on diaphragmatic function&#xD;
      using ultrasonography parameter: thickening fraction of the diaphragmatic muscle during&#xD;
      respiration which defined as [(thickness at end-inspiration - thickness at&#xD;
      end-expiration)/thickness at end-expiration] during spontaneous breathing trial as a primary&#xD;
      outcome and its effect on weaning time and weaning success rate as secondary outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">May 2019</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the effect of doxapram versus theophylline on diaphragmatic function</measure>
    <time_frame>the study drugs will be infused for 1 hour,At the end of 60 min of SBT, the diaphragmatic function will be assessed measuring right and left diaphragmatic thickening fraction in the two groups to be compared as a primary outcome using ultrasound.</time_frame>
    <description>: thickening fraction of the diaphragmatic muscle during respiration which defined as [(thickness at end-inspiration - thickness at end-expiration)/thickness at end-expiration](18) (19) during spontaneous breathing trial as a primary outcome and its effect on weaning time and weaning success rate as secondary outcomes.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Weaning Failure</condition>
  <arm_group>
    <arm_group_label>doxapram group (GROUP D)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients in this group will receive loading dose of (1 mg/kg) followed by an infusion of (1mg/kg/h)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>theophylline group (GROUP T)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the therapeutic loading dose (5mg/kg) followed by an infusion of (0.5 mg/kg/h)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxapram Hydrochloride</intervention_name>
    <description>the diaphragmatic function will be assessed measuring right and left diaphragmatic thickening fraction in the two groups to be compared as a primary outcome using ultrasound. following the administration of the selected drug</description>
    <arm_group_label>doxapram group (GROUP D)</arm_group_label>
    <arm_group_label>theophylline group (GROUP T)</arm_group_label>
    <other_name>Doxapram</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theophylline</intervention_name>
    <description>the diaphragmatic function will be assessed measuring right and left diaphragmatic thickening fraction in the two groups to be compared as a primary outcome using ultrasound. following the administration of the selected drug</description>
    <arm_group_label>doxapram group (GROUP D)</arm_group_label>
    <arm_group_label>theophylline group (GROUP T)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Patients (males and females) in the age group 20 -60 scheduled for&#xD;
        elective open heart surgery ( e.g. coronary artery bypass grafting, valve replacement )&#xD;
        under cardiopulmonary bypass .&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:The preoperative exclusion criteria:&#xD;
&#xD;
          1. Age older than 60 years&#xD;
&#xD;
          2. Preoperative left ventricular ejection fraction less than 30%&#xD;
&#xD;
          3. Chronic obstructive pulmonary disease&#xD;
&#xD;
          4. Significant hepatic disease (alanine aminotransferase or aspartate aminotransferase&#xD;
             &gt;150 U/l).&#xD;
&#xD;
          5. Renal failure (creatinine &gt;200 μm).&#xD;
&#xD;
          6. History of seizure, or stroke.&#xD;
&#xD;
          7. History of diaphragmatic palsy, cervical spine injury, or neuromuscular disease (eg,&#xD;
             myasthenia gravis, Guillain-Barré syndrome).&#xD;
&#xD;
          8. Lesion adjacent to the diaphragm&#xD;
&#xD;
          9. Intra-abdominal hypertension (intra-abdominal pressure ≥12 mm Hg )&#xD;
&#xD;
         10. Known allergy to the study drugs.&#xD;
&#xD;
        The Post enrollment exclusion criteria:&#xD;
&#xD;
          1. Postoperative hemorrhage (chest tube drainage ≥ 200 ml/h).&#xD;
&#xD;
          2. Surgical complications necessitating reoperation.&#xD;
&#xD;
          3. Postoperative cardiac failure necessitating high-dose inotropes or intra -aortic&#xD;
             balloon pump.&#xD;
&#xD;
          4. Refractory hypoxemia (ratio of arterial oxygen tension [PaO2] to fraction of inspired&#xD;
             oxygen [FIO2] &lt;150 mmHg).&#xD;
&#xD;
          5. Occurrence of neurologic deficit.&#xD;
&#xD;
          6. -Myocardial ischemia (ST-segment depression) lasting more than 30 min&#xD;
&#xD;
          7. Failure of spontaneous breathing trial.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samaa ak Rashwan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assisstant proffesor of anesthesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samaa ak Rashwan, MD</last_name>
    <phone>020120159125</phone>
    <email>samakassemrashwan@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beni-Suef University Hospital</name>
      <address>
        <city>Banī Suwayf</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samaa Rashwan, MD</last_name>
      <phone>0201270159125</phone>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 23, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>March 27, 2019</last_update_submitted>
  <last_update_submitted_qc>March 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>Samaa Rashwan</investigator_full_name>
    <investigator_title>Samaa Abou Alkassem Rashwan</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Theophylline</mesh_term>
    <mesh_term>Doxapram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

